Ginger for Health & Longevity - Quick Reference Sheet

Ginger for Health & Longevity

Created on 09/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Ginger settles nausea most reliably in early pregnancy, less so after surgery or cancer treatment. It modestly eases joint pain and more strongly eases menstrual pain, and lowers blood sugar and blood pressure when starting values are raised. Effects on blood fats, body weight and headache are inconsistent. Stomach irritation and heartburn, rising with dose, are what stop most people. (Full Review)

Protocol

Standard dose range
0.5–3 g/day
Dried rhizome powder or an equivalent standardised extract. Above 3 g/day, tolerability falls faster than benefit rises.
Single versus split dosing
Split
Divided doses of 500 mg produced the cleanest nausea results and keep each mucosal exposure below the reflux threshold.
Best time of day
With meals
For nausea, 30–60 minutes before the expected trigger. No circadian rationale; timing follows the meal and the short plasma half-life.
Time to effect
Menstrual pain
First cycle
Menstrual pain responds within the first cycle, with dosing started one to two days before menses.
Nausea
30–60 minutes
Nausea relief is measurable within 30–60 minutes.
Joint pain, soreness, metabolic markers
3–12 weeks
Osteoarthritis pain, muscle soreness and metabolic markers need continuous dosing for 3–12 weeks before an honest assessment.

Benefits

Contraindications
  • Active bleeding disorder or platelet count below 50,000/µL
  • Within 7 days of scheduled surgery or an invasive procedure
  • Symptomatic gallstones or biliary obstruction
  • Active peptic ulcer disease or erosive oesophagitis (Los Angeles grade C or D)
  • Pregnancy above 1 g/day; first trimester using concentrated extracts rather than food-form ginger
  • Documented allergy to ginger or other Zingiberaceae plants (turmeric, cardamom, galangal)
Key Interactions
  • Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran)
  • Antiplatelet drugs (clopidogrel, ticagrelor, prasugrel)
  • Insulin and insulin secretagogues (glipizide, glyburide, gliclazide)
  • Antihypertensives (amlodipine, lisinopril, losartan, hydrochlorothiazide)
  • Narrow-therapeutic-index CYP3A4 substrates (tacrolimus, cyclosporine, everolimus)
  • P-glycoprotein substrates (digoxin, dabigatran, fexofenadine)
  • Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, low-dose aspirin)
  • Over-the-counter acid suppressants (omeprazole, famotidine, antacids)
  • Glucose-lowering supplements (berberine, cinnamon, chromium, alpha-lipoic acid)
  • Blood-pressure-lowering supplements (dietary nitrate, magnesium, potassium, hibiscus)
  • Bleeding-risk supplements (fish oil, garlic, ginkgo, nattokinase, curcumin)

Risk & Side Effects

  • High: Gastrointestinal irritation, reflux and belching
  • Medium: Additive blood-glucose lowering with antidiabetic therapy; additive blood-pressure lowering with antihypertensive therapy
  • Low: Interference with drug metabolism and transport; bleeding risk with anticoagulant or antiplatelet therapy; heavy-metal contamination of commercial products
  • Speculative: Gallstone symptom aggravation; allergic and mucosal hypersensitivity reactions

Monitoring

Marker Target Why
Fasting glucose 75–86 mg/dL Detects both the intended glycaemic benefit and additive hypoglycaemia
Glycated haemoglobin 4.8–5.3% Three-month average glucose; the endpoint that moved most consistently in trials
High-sensitivity C-reactive protein Below 0.8 mg/L The inflammation marker ginger reduced across sixteen trials
Home blood pressure 110–120 / 70–78 mmHg Captures both the benefit and additive hypotension with antihypertensives
Fasting triglycerides Below 80 mg/dL The lipid fraction with the largest reported ginger effect
Low-density lipoprotein cholesterol Below 100 mg/dL, lower with cardiovascular risk Second lipid endpoint; results across meta-analyses conflict
Alanine aminotransferase Below 25 U/L in men, below 20 U/L in women Liver enzyme that fell in fatty-liver trials; also screens for any hepatic irritation
International normalised ratio Individual target set by the prescriber, usually 2.0–3.0 Only relevant on warfarin; confirms no clotting shift from added ginger
Blood lead Below 1.0 µg/dL Relevant only for heavy daily use of bulk ginger powder of unverified origin

Cadence: Baseline before starting, then rechecks at 8 weeks and 6 months, then annually if continuing. Symptom scores and home blood pressure weekly through the first two months; fasting glucose twice weekly for the first month on insulin or an insulin secretagogue.

Qualitative Assessment

  • Nausea frequency and intensity, scored daily around the relevant trigger
  • Joint stiffness on waking and time to loosen up
  • Menstrual pain intensity and number of days affected
  • Post-exercise soreness at 24 and 48 hours after hard eccentric work
  • Post-meal fullness, bloating and reflux frequency
  • Heartburn, belching or aftertaste, as the earliest sign the dose is too high